Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Liquidia Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MORRISVILLE, N.C., AUG. 12, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION(NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. THE COMPANY WILL ALSO HOST A WEBCAST AT8:30 A.M. EASTERN TIMEON AUGUST 12, 2025, TO REVIEW FINANCIAL PERFORMANCE AND PROVIDE A CORPORATE UPDATE.

LIQUIDIA CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MORRISVILLE, N.C., JUNE 23, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION(NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED THE RECEIPT OF AN ADDITIONAL $50.0 MILLION UNDER ITS SIXTH AMENDMENT TO ITS FINANCING AGREEMENT (HCR AGREEMENT) WITH HEALTHCARE ROYALTY (HCRX) UPON THE U.S. DISTRICT COURT FOR THE MIDDLE DISTRICT OF NORTH CAROLINA DENYING UNITED THERAPEUTICS CORPORATION'S REQUEST FOR A PRELIMINARY INJUNCTION AND TEMPORARY RESTRAINING ORDER IN ITS COMPLAINT FILED AGAINST LIQUIDIA AND THE FIRST COMMERCIAL SALE OF YUTREPIA (TREPROSTINIL) INHALATION POWDER.

LIQUIDIA RECEIVES $50 MILLION FROM HEALTHCARE ROYALTY (HCRX) FOLLOWINGFIRST COMMERCIAL SALE OF YUTREPIA

MORRISVILLE, N.C., JUNE 02, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION(NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED THAT LIQUIDIA IS SCHEDULED TO MAKE ITS FIRST COMMERCIAL SHIPMENT OF YUTREPIA (TREPROSTINIL) INHALATION POWDER, MARKING THE FIRST TIME YUTREPIA WILL BE AVAILABLE TO BE PRESCRIBED TO PATIENTS AT SPECIALTY PHARMACIES. THIS MILESTONE WAS ACHIEVED ONLY FIVE BUSINESS DAYS FOLLOWING THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF YUTREPIA ON MAY 23, 2025, FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD).

LIQUIDIA SCHEDULES FIRST COMMERCIAL SHIPMENT OF YUTREPIA (TREPROSTINIL) INHALATION POWDER FOR PATIENTS WITH PAH AND PH-ILD

MORRISVILLE, N.C., MAY 28, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION(NASDAQ: LQDA) ANNOUNCED TODAY THAT THE COMPANY'S CHIEF EXECUTIVE OFFICER DR. ROGER JEFFS, CHIEF FINANCIAL OFFICER AND CHIEF OPERATING OFFICER MICHAEL KASETA, AND CHIEF BUSINESS OFFICER JASON ADAIR WILL BE PROVIDING AN UPDATE ON THE COMPANY'S BUSINESS DURING A FIRESIDE CHAT AT THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCEON WEDNESDAY JUNE 4, 2025, BEGINNING AT 11:05 A.M. ET, INNEW YORK CITY. ACCESS TO A WEBCAST WILL BE AVAILABLE TO INVESTORS AND OTHER INTERESTED PARTIES BY ACCESSING LIQUIDIA'SWEBSITE AT HTTPS://LIQUIDIA.COM/INVESTORS/EVENTS-AND-PRESENTATIONS. AN ARCHIVED, RECORDED VERSION OF THE PRESENTATION WILL BE AVAILABLE ON LIQUIDIA'S WEBSITE FOR AT LEAST 30 DAYS FOLLOWING THE EVENT. ABOUTLIQUIDIA CORPORATION LIQUIDIA CORPORATIONIS A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE. THE COMPANY'S CURRENT FOCUS SPANS THE DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS IN PULMONARY HYPERTENSION AND OTHER APPLICATIONS OF ITS PROPRIETARY PRINTTECHNOLOGY. PRINT ENABLED THE CREATION OF YUTREPIA (TREPROSTINIL) INHALATION POWDER, A DRUG THAT HAS BEEN APPROVED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PHILD). THE COMPANY IS ALSO DEVELOPING L606, AN INVESTIGATIONAL SUSTAINED-RELEASE FORMULATION OF TREPROSTINIL ADMINISTERED TWICE-DAILY WITH A NEXT-GENERATION NEBULIZER AND CURRENTLY MARKETS GENERIC TREPROSTINIL INJECTION FOR THE TREATMENT OF PAH. TO LEARN MORE ABOUTLIQUIDIA, PLEASE VISITWWW.LIQUIDIA.COM.

LIQUIDIA CORPORATION TO PRESENT AT THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

MORRISVILLE, N.C., MAY 23, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION (NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, ANNOUNCED TODAY THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED YUTREPIA (TREPROSTINIL) INHALATION POWDER, A PROSTACYCLIN ANALOG FOR ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) TO IMPROVE EXERCISE ABILITY. YUTREPIA IS THE FIRST AND ONLY PROSTACYCLIN DRY-POWDER FORMULATION ENABLED BY LIQUIDIA'S PROPRIETARY PRINT TECHNOLOGY, WHICH YIELDS UNIFORM, FREE-FLOWING PARTICLES DESIGNED TO ENHANCE DEEP-LUNG DELIVERY VIA AN EASY-TO-USE, LOW-EFFORT DEVICE REQUIRING LESS INSPIRATORY EFFORT.

U.S. FDA APPROVES LIQUIDIA'S YUTREPIA (TREPROSTINIL) INHALATION POWDER FORPATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) ANDPULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD)

MORRISVILLE, N.C., MAY 12, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION (NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED THAT UNITED THERAPEUTICS CORPORATION (UTHR) FILED A COMPLAINT ON MAY 9, 2025, IN THE U.S. DISTRICT COURT FOR THE MIDDLE DISTRICT OF NORTH CAROLINA (CASE NO. 1:25-CV-00368) AGAINST LIQUIDIA ALLEGING INFRINGEMENT OF U.S. PATENT NO. 11,357,782 (THE 782 PATENT). ADDITIONALLY, THE COMPLAINT SEEKS TO ENJOIN LIQUIDIA FROM COMMERCIALIZING YUTREPIA (TREPROSTINIL) INHALATION POWDER IF APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO TREAT PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD).

LIQUIDIA CORPORATION PROVIDES UPDATE ON LITIGATION FILED BY UNITED THERAPEUTICS

MORRISVILLE, N.C., MAY 08, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION(NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. THE COMPANY WILL ALSO HOST A WEBCAST AT8:30 A.M. ETON MAY 8, 2025 TO DISCUSS ITS FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

LIQUIDIA CORPORATION REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSAND PROVIDES CORPORATE UPDATE

MORRISVILLE, N.C., MAY 02, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION (NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, TODAY ANNOUNCED THAT JUDGE KELLY OF THE U.S. DISTRICT COURT FOR THE DISTRICT OF COLUMBIA (DISTRICT COURT) DISMISSED, WITHOUT PREJUDICE, THE CROSS-CLAIM FILED BY UNITED THERAPEUTICS (UTHR) THAT SOUGHT TO CHALLENGE LIQUIDIA'S AMENDMENT TO ITS NEW DRUG APPLICATION (NDA) FOR YUTREPIA (TREPROSTINIL) INHALATION POWDER, WHICH ADDED THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) TO THE PROPOSED LABEL FOR YUTREPIA. IN ITS RULING, THE DISTRICT COURT DETERMINED THAT UTHR'S CLAIM WAS UNRIPE AND THAT UTHR HAD FAILED TO PLAUSIBLY ALLEGE THAT IT HAS STANDING.

DISTRICT COURT DISMISSES DISPUTE FILED BY UNITED THERAPEUTICS AGAINST LIQUIDIA

MORRISVILLE, N.C., MAY 01, 2025 (GLOBE NEWSWIRE) -- LIQUIDIA CORPORATION(NASDAQ: LQDA), A BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR PATIENTS WITH RARE CARDIOPULMONARY DISEASE, ANNOUNCED TODAY THAT IT WILL REPORT ITS FIRST QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, MAY 8, 2025.

LIQUIDIA CORPORATION TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 8, 2025

LIQUIDIA CORPORATION WILL PROVIDE AN OVERVIEW OF THE COMPANY'S BUSINESS AT A FIRESIDE CHAT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE.

Liquidia Corporation

LQDA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Liquidia Corporation

LQDA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LQDA